BioMarin Pharmaceutical (NASDAQ: BMRN) revenue
BioMarin Pharmaceutical reported revenue of $3,221m for fiscal 2025, 12.9% more than in fiscal 2024 ($2,854m). Since fiscal 2016 its revenue has grown by 188.4%, an average growth of 12.5% a year.
BioMarin Pharmaceutical has grown its revenue for 4 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2021, −0.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $3,221m | +12.9% | $409.5m | 12.7% |
| 2024 | $2,854m | +18.0% | $484.2m | 17.0% |
| 2023 | $2,419m | +15.4% | $185.8m | 7.7% |
| 2022 | $2,096m | +13.5% | $161.0m | 7.7% |
| 2021 | $1,846m | −0.8% | −$82.3m | −4.5% |
| 2020 | $1,860m | +9.2% | −$43.4m | −2.3% |
| 2019 | $1,704m | +14.3% | −$100.5m | −5.9% |
| 2018 | $1,491m | +13.5% | −$123.5m | −8.3% |
| 2017 | $1,314m | +17.6% | −$14.7m | −1.1% |
| 2016 | $1,117m | — | −$803.4m | −71.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
BioMarin Pharmaceutical revenue compared with its sector
By revenue for its latest fiscal year, BioMarin Pharmaceutical ranks 82nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; BioMarin Pharmaceutical, 12.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 80th | Surgery Partners | $3,309m | 6.2% |
| 81st | AdaptHealth | $3,245m | −0.5% |
| 82nd | BioMarin Pharmaceutical | $3,221m | 12.9% |
| 83rd | Veeva Systems | $3,195m | 16.3% |
| 84th | Brookdale Senior Living | $3,194m | 2.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of BioMarin Pharmaceutical
- How much revenue did BioMarin Pharmaceutical make in fiscal 2025?
- BioMarin Pharmaceutical reported revenue of $3,221m for fiscal 2025, compared with $2,854m in fiscal 2024.
- How much has the revenue of BioMarin Pharmaceutical grown?
- Between fiscal 2016 and fiscal 2025 it went from $1,117m to $3,221m: 188.4% more, an average growth of 12.5% a year.
- What was the best year for revenue at BioMarin Pharmaceutical?
- Of its last 10 fiscal years, fiscal 2025, with $3,221m.
- Where does BioMarin Pharmaceutical rank in its sector by revenue?
- It ranks 82nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for BioMarin Pharmaceutical come from?
- From the annual report (Form 10-K) that BioMarin Pharmaceutical files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that BioMarin Pharmaceutical files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on BioMarin Pharmaceutical: the BioMarin Pharmaceutical page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.